Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blue dye cream takes on tough skin cancer in new trial

NCT ID NCT07311070

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a cream made from methylene blue, a common dye, on people with advanced basal cell carcinoma (a type of skin cancer) that cannot be treated with surgery or radiation. Twenty adults will apply the cream to their tumors every two days for one month. Researchers will measure whether the tumors shrink and how well the skin heals, with follow-up for six months. The goal is to find a safe, non-invasive option for patients who have run out of standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
methylene blue cream applied to the skin
What this could lead to
If it works, this could offer a non-invasive, low-cost treatment option for people with advanced skin cancer who cannot have surgery or radiation.
What could go wrong
This is a small early-phase trial with only 20 participants and no comparison group. The treatment may not shrink tumors or could cause skin irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histopathologically confirmed diagnosis of morpheaform, infiltrative, or noduloulcerative basal cell carcinoma (BCC) * Provision of written informed consent to participate in the study * Lack of willingness or eligibility for surgical excision or radiotherapy, or contraindication to intralesional medical treatments such as interferon-alpha or 5-fluorouracil (5-FU) * Age ≥ 18 years * Lesion size \< 2 cm in diameter * Presence of multiple lesions Exclusion Criteria: * Superficial or nodular subtype of basal cell carcinoma * Withdrawal of consent at any stage of the study * Pregnancy or breastfeeding * History of severe adverse reactions to medications * Inability or unwillingness to attend follow-up visits * History of cardiovascular disease * History of thromboembolic disorders * Prior radiotherapy to the affected area * History of chronic arsenic exposure * Immunodeficiency * Presence of severe systemic illness * Known allergy or hypersensitivity to methylene blue * History of bleeding disorders or abnormal coagulation * Severe inflammatory or dermatologic conditions in the treatment area * Failure to complete the full course of treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced basal cell carcinoma (BCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mashhad University of Medical Sciences

    Mashhad, Razavi Khorasan Province, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.